In this study, we obtained 50 pairs of colorectal primary tumors and adjacent noncancerous colorectal tissues (~3 cm away from tumors) from CRC patients undergoing colorectal resection in the First Affiliated Hospital of Wenzhou Medical University. None of the patients received any conventional treatment before surgery. The clinical features of these patients were shown in Table 1 . We confirmed tumor tissues by staining for cell proliferation using the cell-cycle marker Ki67 with anti-Ki67 antibody (ab15580, 1:100 dilution; Abcam, Cambridge, UK), biotinylated goat anti-rabbit IgG secondary antibody (ab64256, 1:300 dilution; Abcam), and a 3,3-diaminobenzidine (DAB) Kit (Vector Laboratories, Peterborough, UK), which was processed by immunohistochemistry using standard method [31 (link)]. Human tissue samples were used to evaluate the levels of circ_0089153, miR-198, and SENP1. The study protocol was approved by the Ethics Committee of the First Affiliated Hospital of Wenzhou Medical University and informed consent was provided by all subjects.
Correlation between circ_0089153 expression and the clinical features of CRC patients (n = 50)
| Clinical feature | Circ_0089153 expression (n) | ||
|---|---|---|---|
| High | Low | P value | |
| Age | 0.9453 | ||
| ≤50 years | 13 | 10 | |
| >50 years | 15 | 12 | |
| Gender | 0.5356 | ||
| Female | 14 | 15 | |
| Male | 12 | 9 | |
| TNM stage | <0.0001 | ||
| I+ II | 5 | 20 | |
| III | 22 | 3 | |
| Tumor size (cm) | 0.0003 | ||
| ≤3 | 7 | 15 | |
| >3 | 23 | 5 | |
